drugset / Trial / NCT00872976
Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the recommended dose for the combination of dasatinib and bendamustine in chronic lymphocytic leukemia (CLL).
Timeline
- Start
- 2009-05
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Bendamustine | Small molecule | 70 mg/m2 | Intravenous |
| Subject | Bendamustine | Small molecule | 100 mg/m2 | Intravenous |
| Subject | dasatinib anhydrous | Small molecule | 50 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 80 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | Oral |